Clinical Research Directory

Inclusion Criteria: * Pathologically confirmed pancreatic adenocarcinoma, either initially diagnosed or recurrent locally advanced disease. The maximum dimension of the treatment target must be =\<10 cm. Locally advanced disease defined as: T 1-2N+MO or T3-4 NxMo, or borderline resectable and unresectable adenocarcinoma without distant metastatic disease or resectable T3-4 NxMo disease or M1 with controlled distant disease * Inoperable conditions with resectable disease (T1-2NoMo) * Karnofsky performance status of 60% or better. Received recent chemotherapy for pancreatic cancer or completed chemotherapy \> 5 years ago for malignancies other than pancreatic cancer with no evidence of the second malignancy at study entry * Radiation therapy completed \> 5 years ago for malignancies other than pancreatic cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field and no evidence of the second malignancy at study entry * All malignant disease must be able to be encompassed within a single irradiation field * Absolute neutrophil count (ANC) greater than or equal to 1500/uL * Radiographically assessable disease * Platelet count greater than or equal to 100,000/uL * Serum creatinine less than or equal to 2.0 mg/dL and total bilirubin less than or equal to 2.0 mg/dL in the absence of biliary obstruction. If biliary obstruction is present, biliary decompression will be required, either endoscopic placement of a biliary stent or percutaneous transhepatic. Once biliary drainage has been established, institution of protocol therapy may proceed when the total bilirubin falls to 4.0 mg/dL or lower * Calculated creatinine clearance of \>= 35. * Awareness of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts Exclusion Criteria: * Known allergy to Zometa or to anti-emetics appropriate in conjunction with protocol-directed therapy * Uncontrolled inter-current illness that might jeopardize the ability of the subject to receive the protocol therapy with reasonable safety. This may include, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia * Pregnant and nursing women * Prior malignancy except adequately treated basal cell or squamous cell skin cancer, adequately treated non-invasive carcinomas, or be disease-free for at least 5 years from other cancers * Active duodenal ulcer or bleeding or history of a gastrointestinal fistula or perforation or other significant bowel problems (severe nausea, vomiting, inflammatory bowel disease and significant bowel resection) * Known human immunodeficiency virus (HIV) infection, or hepatic insufficiency * Not currently receiving or have received Zometa within 3 weeks prior to study treatment with Zometa